2-(4-溴苯基)-4-(氯甲基)-1,3-恶唑 | 22091-38-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2-(4-溴苯基)-4-(氯甲基)-1,3-恶唑
• 英文名称: 2-(4-bromophenyl)-4-(chloromethyl)oxazole
• 英文别名: 2-(4-bromo-phenyl)-4-chloromethyl-oxazole；4-Chlormethyl-2-(4-bromphenyl)-oxazol；2-(p-Bromphenyl)-4-chlormethyloxazol；2-(4-Bromophenyl)-4-(chloromethyl)-1,3-oxazole
• CAS: 22091-38-9
• 化学式: C₁₀H₇BrClNO
• mdl: MFCD11200985
• 分子量: 272.529
• InChiKey: KZSDQYSWKWLFJE-UHFFFAOYSA-N

物化性质

• 熔点：
  115-117 °C
• 沸点：
  365.6±52.0 °C(Predicted)
• 密度：
  1.560±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-溴苯基)-4-(氯甲基)-1,3-恶唑 在 盐酸 、 sodium carbonate 作用下， 以 乙醇 、 氯仿 为溶剂， 生成 1-[2-(4-bromo-phenyl)-oxazol-4-ylmethyl]-3-phenyl-thiourea
  参考文献：
  名称：

  2-芳基-4-氯甲基-恶唑Mitt.杂环化合物中的Delepine反应

  摘要：

  借助Hantzsch反应制备了许多2-芳基-4-氯甲基恶唑，同时使用Delépine反应获得相应的氨甲基衍生物。

  DOI：

  10.1002/ardp.19713040608
• 作为产物：
  描述：

  methyl 2-(4-bromophenyl)oxazole-4-carboxylate 在 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.0h， 生成 2-(4-溴苯基)-4-(氯甲基)-1,3-恶唑
  参考文献：
  名称：

  Discovery of the disubstituted oxazole analogues as a novel class anti-tuberculotic agents against MDR- and XDR-MTB

  摘要：

  A high-throughput screening effort on 45,000 compounds resulted in the discovery of a disubstituted oxazole as a new structural class inhibitor of Mycobacterium tuberculosis (Mtb). In order to improve the activity and investigate the SAR of this scaffold, a series of disubstituted azole analogues have been designed and synthesized. The newly synthesized compounds 1a-y were evaluated for their in vitro anti-TB activity versus replicating, multi-and extensive drug resistant Mtb strains. All the compounds, except 1o, 1p and 1q, showed potent anti-TB activity with MIC of 1-64 mg/L. The test of broad spectrum panel revealed that this series are specific to Mtb. The cytotoxicity assessment indicated that the compounds were not cytotoxic against HEK 293 cells. The compounds could have a novel mechanism to anti-Mtb as they can inhibit drug sensitive and drug resistant Mtb. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.09.072

文献信息

• Substituted naphthylenes for the treatment of non-insulin dependent diabetes mellitus
  申请人：Wyeth

  公开号：US20030216442A1

  公开（公告）日：2003-11-20

  This invention provides compounds of formula I, having the structure 1 wherein R 1 , R 4 , A, and Z are as defined in the specification, or a pharmaceutically acceptable salt thereof, that are useful in treating metabolic disorders mediated by insulin resistance or hyperglycemia.

  这项发明提供了具有结构的I式化合物，其结构如下： 其中R 1 ，R 4 ，A和Z如规范中定义，或其药学上可接受的盐，可用于治疗由胰岛素抵抗或高血糖介导的代谢紊乱。
• [EN] OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] DERIVES D'OXAZOLE EN TANT QU'AGENTS DE RECEPTEUR D'HISTAMINE H3, PREPARATION ET UTILISATIONS THERAPEUTIQUES
  申请人：LILLY CO ELI

  公开号：WO2006019833A1

  公开（公告）日：2006-02-23

  The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently -(C1-C7) alkyl(optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence -H, -halogen, or -CH3.

  本发明公开了具有组分I（I）的新型芳基噁唑化合物或其药学上可接受的盐，其具有组胺H3受体拮抗剂或逆向激动剂活性，以及制备和使用这些化合物的方法。在另一实施方案中，本发明公开了包括组分I化合物的药物组合物，以及使用这些组合物治疗肥胖、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。组分I（I）或其药学上可接受的盐，其中：m在每次出现时独立地为1、2或3，Z独立地表示碳（用氢或此处指示的可选取代基团取代）或氮，但当Z为氮时，R6不连接到Z；R1和R2独立地为-(C1-C7)烷基（可选地用一到三个卤素取代），或者R1和R2以及它们连接的氮形成氮杂环戊二烷环、吡咯环或哌啶环，进一步地，所形成的氮杂环戊二烷、吡咯环或哌啶环可以用R5取代一到三次；R6在每次出现时独立地为-H、-卤素或-CH3。
• Nitrierung und Halogenierung einiger 2-Aryl-4-chlormethyl-oxazole. XXIII. Mitt. Heterozyklische Verbindungen
  作者：I. Simiti、Elena Chindris

  DOI：10.1002/ardp.19723050706

  日期：——

  Es wird die Nitrierung und Bromierung des 2‐Aryl‐4‐chlormethyloxazols untersucht. Bei der Bromierung ist die Stellung 5 des Oxazolringes besonders reaktiv. Bei der Nitrierung wird die Nitrogruppe im Benzolring immer in ortho‐Stellung zum vorhandenen Substituenten eingeführt.

  研究了2-芳基-4-氯甲基恶唑的硝化和溴化。恶唑环的 5 位在溴化过程中特别具有反应性。在硝化过程中，苯环中的硝基总是在取代基的邻位引入。
• Heterocyclen, XXXIX. Darstellung der 2-Aryl-4-formyloxazole mit der Sommelet-Reaktion
  作者：I. Simiti、E. Chindris

  DOI：10.1002/ardp.19753080904

  日期：——

  Das Verhalten von 2‐Aryl‐4‐chlormethyl‐oxazolen und 2‐Aryl‐4‐chlormethyl‐5‐brom‐oxazolen unter den Bedingungen der direkten und indirekten Sommelet‐Reaktion wird beschrieben.

  描述了2-芳基-4-氯甲基-恶唑和2-芳基-4-氯甲基-5-溴-恶唑在直接和间接Sommelet反应条件下的行为。
• Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses
  申请人：Beavers Selsam Lisa

  公开号：US20070197604A1

  公开（公告）日：2007-08-23

  The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently —(C 1 —C 7 ) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence —H, -halogen, or —CH 3 .

  本发明披露了式I（I）的新型芳基噁唑化合物或其药学上可接受的盐，具有组胺H3受体拮抗剂或反向激动剂活性，以及制备和使用这些化合物的方法。在另一实施例中，本发明披露了包含式I化合物的药物组合物，以及使用这些组合物治疗肥胖症、认知缺陷、嗜睡病和其他组胺H3受体相关疾病的方法。其中，式I（I）或其药学上可接受的盐，其中：m在每次出现时独立地为1、2或3，Z独立地表示碳（用氢或此处指示的可选取代基替换）或氮，但当Z为氮时，R6不与Z连接；R1和R2独立地为—（C1-C7）烷基（可选取代有1至3个卤素），或R1和R2以及它们所连接的氮形成一个氮杂环、吡咯烷环或哌啶环，其中进一步形成的氮杂环、吡咯烷环或哌啶环可以用R5取代1至3次；R6在每次出现时独立地为—H、-卤素或—CH3。